Opinion|Podcasts|November 22, 2024
Future Landscape of BTK Inhibitors for CSU
Key Takeaways
- Biologics, especially monoclonal antibodies, provide targeted, personalized treatment options in CSU management, improving efficacy and safety profiles.
- BTK inhibitors offer a novel therapeutic approach by modulating B-cell receptor signaling, potentially benefiting patients unresponsive to conventional therapies.
Panelists discuss the current and future roles of advanced treatments, including biologics and Bruton tyrosine kinase (BTK) inhibitors, in the management of chronic spontaneous urticaria (CSU), highlighting their potential to improve patient outcomes and the evolving landscape of treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you describe what you see as the current and future role of advanced treatments such as biologics and BTK inhibitors in CSU management?
Advertisement
Related to this article
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD
5